Beta Bionics, Inc. filed an 8-K with the SEC on September 17, 2026, disclosing that on September 15, 2026, it entered into an underwriting agreement for a public offering expected to raise approximately $150.0 million in gross proceeds.

Key Highlights

  • Offering size: 7,652,175 shares of common stock priced at $17.25 per share to the public.
  • Pre-funded warrants: An additional 1,043,484 shares may be purchased via pre-funded warrants at $17.2499 per share, equal to the public offering price less the $0.0001 exercise price per warrant.
  • Gross proceeds: Approximately $150.0 million expected, before deducting underwriting discounts, commissions, and estimated offering expenses.
  • Overallotment option: Underwriters received a 30-day option to purchase up to 1,304,348 additional shares at the public offering price, less underwriting discounts and commissions.
  • Expected closing: September 17, 2026, subject to customary closing conditions.
  • Intended use of proceeds: General corporate purposes, which may include commercialization of Mint, manufacturing expansion, research and development, product enhancements, potential strategic opportunities, and working capital.

Beta Bionics Underwriting Agreement and Offering Terms

According to the filing, Beta Bionics, Inc. (NASDAQ:BBNX) entered into an underwriting agreement on September 15, 2026, with J.P. Morgan Securities LLC, Piper Sandler & Co., Wells Fargo Securities, LLC, and Leerink Partners LLC, as representatives of the several underwriters. The agreement covers the issuance and sale of 7,652,175 shares of common stock, par value $0.0001 per share, at a public offering price of $17.25 per share. In lieu of shares to certain investors, the company also offered pre-funded warrants to purchase 1,043,484 shares at $17.2499 per share.

The company disclosed that gross proceeds from the offering are expected to be approximately $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The filing noted that the offering is being made pursuant to an effective registration statement on Form S-3 and accompanying prospectus (Registration Statement No. 333-293702), previously filed with the SEC, and a prospectus supplement thereunder.

The company stated it expects to use net proceeds for general corporate purposes, which may include costs associated with the commercialization of Mint, expansion of manufacturing facilities, research and development and clinical development, investment in product enhancements, potential strategic opportunities, and working capital and operating expenses. The filing notes that statements regarding the completion, timing, size, and use of proceeds from the offering are forward-looking statements subject to the company's cautionary language, including risks related to market conditions and satisfaction of customary closing conditions.

What Was Disclosed

Beta Bionics disclosed the terms of a public stock offering entered into on September 15, 2026, including share counts, pricing, pre-funded warrant details, gross proceeds of approximately $150.0 million, an underwriter overallotment option, and intended use of net proceeds.